Figure 2
AML: intensifying induction therapy (overall survival from diagnosis). Randomized study conducted by ECOG in adults younger than 60 years comparing daunorubicin (DnR) 45 versus 90 mg/m2 for 3 days, both with cytarabine 100 mg/m2 for 7 days. (A) All study patients. (B) Patients with favorable and intermediate cytogenetics. Reprinted from Fernandez et al4 with permission. (C) Similar randomized study conducted by HOVON/SAKK in older adults (older than 60 years). Reprinted from Lowenberg et al55 with permission.
